Drug Policy in the Czech Republic

Slides:

Advertisements

Similar presentations

National Health Account in Taiwan: An update Chung-Fu Lan National Yang-Ming University Pi - Joen Lee Department of Health, ROC (Taiwan) Seoul, 5th SHA.

Advertisements

LIST OF DRUGS COVERED BY HEALTH INSURANCE FUND OF THE REPUBLIC OF MACEDONIA Ms. Maja Parnardzieva – Zmejkova, MSc, CEO October 2011.

AFAMS Intro to ATC Drug Codes (Dari) EO Part 16.

Research and Systems Development for National Drug Account, Thailand Nusaraporn Kessomboon Rungpetch Sakulbumrungsil Inthira Kanjanapiboon Siripa Udomuksorn.

Use of Doppler Techniques (Continuous-Wave, Pulsed-Wave, and Color Flow Imaging) in the Noninvasive Hemodynamic Assessment of Congenital Heart Disease.

Performance Assessment of the Juaboso District Office of the National Health Insurance Authority Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.

Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary: A Retrospective.

Managing Cancer Pain: Basic Principles and Invasive Treatments

Value in Health Regional Issues

Evaluation of Proteinuria

Investigating the Economic Impacts of New Public Pharmaceutical Policies in Greece: Focusing on Price Reductions and Cost-Sharing Rates Siskou Ch. Olga,

Diagnostic Options for Assessment of Postmenopausal Bleeding

Eric Nsiah-Boateng, MPH, Moses Aikins, PhD

The Development of the Romanian Scorecard HTA System

Using Dynamic Transmission Modeling to Determine Vaccination Coverage Rate Based on 5-Year Economic Burden of Infectious Disease: An Example of Pneumococcal.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Value in Health Regional Issues

Drug Policy in Slovakia

Systematic Review of Economic Evaluation Literature in Ghana: Is Health Technology Assessment the Future? Emmanuel Ankrah Odame, MBCHB, MPH Value in.

Drug Policy in Croatia Value in Health Regional Issues

The Update of the Mexican Health Care Formulary and Supply Catalog in the Context of the Health Technology Assessment Pedro Rizo Ríos, MD, MHSM, Aurora.

Health-Related Quality-of-Life Measures: Evidence from Tunisian Population Using the SF-12 Health Survey Moheddine Younsi, PhD Value in Health Regional.

Disability and quality of life of patients with knee or hip osteoarthritis in the primary care setting and factors associated with general practitioners'

Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an Evidence-based HTA Methodology for Evaluating Off-Patent Pharmaceuticals (OPPs)

Value in Health Regional Issues

The Process of Privatization of Health Care Provision in Poland

Use and costs of concomitant medicines in epileptic patients in Poland: A 12-month prospective multicentre study Beata Majkowska-Zwolińska, Joanna Jędrzejczak,

Drug Policy in Bulgaria

Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary: A Retrospective.

Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary Zoltán Kaló, MSc, MD, PhD, József Bodrogi, MSc, Imre Boncz,

Combining access to innovation and financial sustainability

Cost-Benefit Analysis and Assessment of Quality of Care in patients with Hemophilia undergoing treatment at National Rural Health Mission in Maharashtra,

What Is Important During the Selection of Traditional Chinese Medicine (TCM) in a Health Care Reimbursement or Insurance System?” Critical Issues of Assessment.

Lip edema Journal of the American Academy of Dermatology

The Potential Effects of Implementing the 2013 ACC/AHA Cholesterol Guidelines on the Use of Statins in a Large Health Maintenance Organization in Israel

Bernadette A. Tumanan-Mendoza, MD, MScE, MHE, Victor L. Mendoza, MD

Patient-Reported Outcomes in Latin America: Implementation in Research and Role in Emerging HTA Systems Randall Winnette, MSc, Victor Zárate, MD, MSc,

Advancing the Visibility, Impact, and Quality Metrics of Value in Health Regional Issues Dan Greenberg, PhD, Imre Boncz, MD, MSc, PhD, Habil, Ahmed Awaisu,

Omneya Mohamed, PhD, David H. Kreling, PhD

Public policy and the practicing physician

Malcolm O. Perry, MD, Richard Kempczinski, MD

Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy? Fei-Li.

A Framework for Applying Health Technology Assessment in Cyprus: Thoughts, Success Stories, and Recommendations Panagiotis Petrou, MBA, PhD, PhDc, Michalis.

Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary András Inotai, PharmD, PhD, Zsolt Abonyi-Tóth, MSc, György.

Volume 130, Issue 6, (September 2007)

Diffuse pruritic papules

Antidepressants and Brain Neurochemistry

Generalized Cost-Effectiveness Analysis of Pharmaceutical Interventions for Primary Prevention of Cardiovascular Disease in Thailand Panrasri Khonputsa,

The Methodological Challenges for the Estimation of Quality of Life in Children for Use in Economic Evaluation in Low-Income Countries Travor Mabugu,

Cost-Effectiveness Analysis Expands its Reach Worldwide

Support Your Specialty

Jing Wu, PhD, Ning Yue, MS, Weiwei Xu, PhD

Value in Health Regional Issues

HTA and Its Use in Drug Policies: Singapore

Prediction of Change in Prescription Ingredient Costs and Co-payment Rates under a Reference Pricing System in South Korea Ji Haeng Heo, MS, Karen L.

Dossier System as a Practical Tool for Compiling Reimbursement Lists

Colombian Health System on its Way to Improve Allocation Efficiency—Transition from a Health Sector Reform to the Settlement of an HTA Agency Nicolás.

Performance Assessment of the Juaboso District Office of the National Health Insurance Authority Paul Effah, MBA, Kingsley Opoku Appiah, PhD, FCCA, Patience.

Social Cost of Substance Abuse in Russia

Drug Policy in Hungary Value in Health Regional Issues

Evaluation of Quality of Pharmacoeconomic Studies in Asia-Pacific Region and Identification of Influencing Variables Prabhakar Pandey, MPharm, Rishabh.

Widespread hyperpigmented rash present for 1 year

Joshua P. Metlay, Daniel E. Singer Clinical Microbiology and Infection

J.Dennis Baker, MD Journal of Vascular Surgery

Abdol Majid Cheraghali, PhD, Peyman Eshghi, MD

Impact of antibiotic restrictions: the patient's perspective

“The more things change…”: The challenges ahead

Managing Cancer Pain: Basic Principles and Invasive Treatments

James A. DeWeese, MD Journal of Vascular Surgery

Volume 134, Issue 6, (September 2008)

Presentation transcript:

Drug Policy in the Czech Republic Jana Skoupá, MD Value in Health Regional Issues Volume 13, Pages 55-58 (September 2017) DOI: 10.1016/j.vhri.2017.08.002 Copyright © 2017 Terms and Conditions

Fig. 1 Simplified structure of the P&R process for outpatient drugs in the Czech Republic. HTA, health technology assessment; P&R, pricing and reimbursement; RWE, real-world evidence. Value in Health Regional Issues 2017 13, 55-58DOI: (10.1016/j.vhri.2017.08.002) Copyright © 2017 Terms and Conditions

Fig. 2 Mean duration (d) of the P&R process in the Czech Republic per Anatomical Therapeutic Chemical classification system group. Numbers in parentheses indicate the number of individual proceedings. Labels: A, alimentary tract and metabolism; B, blood and blood-forming organs; C, cardiovascular system; D, dermatologicals; G, genitourinary system and sex hormones; H, systemic hormonal prep, excluding sex hormones; J, general anti-infectives for systemic use; L, antineoplastic and immunomodulating agents; M, musculoskeletal system; N, nervous system; P, antiparasitic products; R, respiratory system; S, sensory organs; V, various. P&R, pricing and reimbursement. Value in Health Regional Issues 2017 13, 55-58DOI: (10.1016/j.vhri.2017.08.002) Copyright © 2017 Terms and Conditions